Literature DB >> 11776328

Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells.

Y Q Chen1, J Sloan-Lancaster, D T Berg, M A Richardson, B Grinnell, J Tseng-Crank.   

Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (SERPIN) specific for tissue-type and urokinase-like plasminogen activators. High plasma PAI-1 activity is a risk factor for thrombotic diseases. Due to the short half-life of PAI-1, regulation of PAI-1 gene expression and secretion of active PAI-1 into the blood stream is important for hemostatic balance. We have investigated transcriptional control of PAI-1 gene expression in bovine aortic endothelial cells (BAECs) and human cell lines using PAI-1 5' promoter-luciferase reporter assays. Contrary to the cytokine-induced up-regulation of PAI-1 mRNA and protein levels, we found that only transforming growth factor-beta (TGF-beta) was efficient in inducing PAI-1 promoter activation. Tissue necrosis factor-alpha (TNF-alpha) induced a small luciferase activity with the 2.5 kb PAI-1 promoter, but not with the PAI-800/4G/5G and p3TP-lux promoters. Next we investigated whether a lack of response to TNF-alpha was due to deficient signaling pathways. BAECs responded to TNF-alpha with robust NFkappaB promoter activation. TGF-beta activated the p38 MAP kinase, while TNF-alpha activated both the SAPK/JNK and p38 MAP kinases. The ERK1/2 MAP kinases were constitutively activated in BAECs. BAEC therefore responded to TNF-alpha stimulation with activation of the MAP kinases and the NFkappaB transcriptional factors. We further measured the messenger RNA stability under the influence by TGF-beta and TNF-alpha and found no difference. PAI-1 gene activation by TNF-alpha apparently is yet to be defined for the location of the response element and/or the signaling pathway, while TGF-beta is the most important cytokine for PAI-1 transcriptional activation through its 5' proximal promoter.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11776328

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  8 in total

1.  Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression.

Authors:  Mark D Sternlicht; Alison M Dunning; Dan H Moore; Paul D P Pharoah; David G Ginzinger; Koei Chin; Joe W Gray; Frederic M Waldman; Bruce A J Ponder; Zena Werb
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

Review 2.  PAI-1 in tissue fibrosis.

Authors:  Asish K Ghosh; Douglas E Vaughan
Journal:  J Cell Physiol       Date:  2012-02       Impact factor: 6.384

3.  Aldosterone and TGF-β₁ synergistically increase PAI-1 expression in hepatic stellate cells of rats.

Authors:  Sheng-Lan Wang; Hui-Min Wu; Cheng-Zhi He; Li Yang; Heng-Jun Gao; Chang-Qing Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 4.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis.

Authors:  Rui-Ming Liu
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

5.  No association of the plasminogen activator inhibitor-1 promoter 4G/5G polymorphism with inhibitor level during basal transcription in vitro.

Authors:  Mei Zhan; Yuling Zhou; Zhong Chao Han
Journal:  Int J Hematol       Date:  2004-05       Impact factor: 2.490

6.  Investigating the association between polymorphisms in connective tissue growth factor and susceptibility to colon carcinoma.

Authors:  Abrar Ahmad; Shlear Askari; Rahel Befekadu; Victoria Hahn-Strömberg
Journal:  Mol Med Rep       Date:  2014-12-11       Impact factor: 2.952

7.  Effect of TNF-alpha on human ARPE-19-secreted proteins.

Authors:  Eunkyung An; Heather Gordish-Dressman; Yetrib Hathout
Journal:  Mol Vis       Date:  2008-12-11       Impact factor: 2.367

8.  PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.

Authors:  Xin Xu; Yanqi Xie; Yiwei Lin; Xianglai Xu; Yi Zhu; Yeqing Mao; Zhenghui Hu; Jian Wu; Hong Chen; Xiangyi Zheng; Jie Qin; Liping Xie
Journal:  Exp Ther Med       Date:  2012-10-02       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.